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Abstract
A series of triazole-containing novobiocin analogues has been designed, synthesized and their
inhibitory activity determined. These compounds contain a triazole ring in lieu of the amide
moiety present in the natural product. The anti-proliferative effects of these compounds were
evaluated against two breast cancer cell lines (SKBr-3 and MCF-7), and manifested activities
similar to their amide-containing counterparts. In addition, Hsp90-dependent client protein
degradation was observed via western blot analysis, further supporting a common mode of Hsp90
inhibition for both structural classes.
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Current cancer therapy strategies utilize the administration of multiple drug regimens that
aim to halt multiple malignant processes simultaneously. Heat shock protein 90 (Hsp90)
represents an exciting target for the treatment of cancer, as inhibition of this chaperone can
affect multiple proteins that are directly associated with all six hallmarks of cancer.1–4
Hsp90 is a 90 kDa molecular chaperone and is intimately involved in the post-translational
conformational maturation of nascent polypeptides as well as the re-folding of denatured
proteins and the re-solubilization of protein aggregates.5 Pharmacological inhibition of
Hsp90 effectively inhibits protein substrates dependent upon Hsp90 for conformational
maturation, resulting in destabilization of the Hsp90-client protein heteroprotein complex,
which leads to degradation of substrates through the ubiquitin-proteasome pathway.4,6–7
Many proteins associated with malignant progression; including steroid hormone receptors,
transcription factors and protein kinases, rely upon Hsp90 to reach their biologically active,
three-dimensional conformation. As such, Hsp90 has emerged as a promising anti-cancer
target, with more than 20 clinical trials currently in progress with small molecules that bind
the N-terminal ATP binding site.8
The Hsp90 protein folding machinery requires co-chaperones and partner proteins to aid in
the topological reorientation of polypeptide substrates.7 This protein folding process is ATP-
dependent, with hydrolysis occurring at the N-terminal nucleotide binding site of the Hsp90
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homodimer.9 All Hsp90 inhibitors currently in clinical trials bind this region. Although
promising data has emerged from these trials, many of these compounds exhibit undesired
toxicity and/or complicated dosing schedules. In contrast, the development of Hsp90
inhibitors that target other small molecule binding regions, such as that contained in the C-
terminus remains minimally investigated.10 For example, novobiocin was shown to bind the
C-terminus of Hsp90 in 2000 and provided the first example of a small molecule binding
site outside of the N-terminus. 11–12 However, novobiocin manifests only modest inhibitory
activity (500 µM). Since 2000, other inhibitors of the C-terminus have also been identified,
but the development of such compounds has not been thoroughly sought after.10
Since the discovery of the Hsp90 C-terminal binding site, analogues of novobiocin have
been synthesized and evaluated, with many of the compounds manifesting micromolar
antiproliferative activities.13–17 Modifications to both the coumarin core and benzamide
side chain have been pursued, resulting in the production of preliminary structure–activity
relationships (SAR). The hydrogen bonding capabilities and the geometry of the amide bond
appear to be important for novobiocin binding, however modifications to this moiety have
not been fully realized to evaluate SAR. It was proposed that inclusion of 1,2,3-triazoles as a
bioisosteric replacement for the amide moiety could facilitate SAR analysis for the aryl side
chain by utilizing “click” chemistry. The triazole serves as a bioisostere due to similarities in
both electronic and spacial characteristics to the amide bond. In addition, it is metabolically
stable to hydrolysis and easily incorporated into small molecules.18–19 In contrast, triazoles
exhibit different hydrogen bonding capabilities and an altered geometry as compared to their
amide counterparts, which aids in further elucidation of SAR. For these reasons, a series of
1,2,3-triazole containing novobiocin analogues was prepared. The design, synthesis, and
biological evaluation of these compounds are described herein.
Synthesis of the 8-methyl coumarin core, as found in novobiocin, was commenced with
commercially available 2-methyl resorcinol, 1 [Scheme 1]. Compound 1 was formylated
under Vilsmeier-Haack conditions enlisting POCl3 and DMF, followed by hydrolysis to
afford formyl-resorcinol 2. Similar to the procedure of Sivakumar and co-workers,
condensation of 2 with N-acetyl glycine in the presence of acetic anhydride, produced the
bis-acylated coumarin, 3.20 Deacetylation of both the phenol and amine was accomplished
upon heating with HCl and EtOH to afford 3-amino-7-hydroxy-8-methyl-coumarin, 4.
Conversion of amino-coumarin 4 to the azide, which was required for the copper-catalyzed
Huisgen 1,3-dipolar cycloaddition, was accomplished by in-situ generation of the 3-
diazonium salt upon treatment with sodium nitrite in aqueous acid, followed by the addition
of sodium azide to afford 3-azido-coumarin, 5a.20 Acetylation of coumarin 5a was
accomplished with acetic anhydride in pyridine to afford 5b.
Upon the generation of compounds 5a and 5b, the copper-catalyzed Huisgen 1,3-dipolar
cycloaddition with the corresponding alkynes was set to generate compounds 6–14a and 6–
14b [Scheme 2]. Standard conditions were used to effect this transformation, and a
combination of DMSO and H2O were found most suitable for optimal product formation.
Alkynes 6–10 were chosen to investigate the electronic nature of the aryl side chain,
including neutral (Me), electron withdrawing (F) and electron donating (OMe, NMe2)
properties as originally identified during classical novobiocin SAR studies.13 Alkynes 11–14
were chosen based on prior observations that the analogous amide derivatives manifested
good anti-proliferative activities against multiple cell lines,13 and thus provide direct
comparison between amide and triazole analogues.
Completion of the triazole-containing novobiocin analogues was achieved by incorporation
of the noviose sugar into 6–14a [Scheme 3]. The phenols of compounds 6–14a were
noviosylated with the trichloroacetimidate of noviose carbonate (15) in the presence of
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boron trifluoride etherate.21 Solvolysis of the cyclic carbonate with methanolic triethylamine
afforded novobiocin analogues 6–14c.
Upon preparation of compounds 6–14 a, b and c, their growth inhibitory activities against
MCF-7(ER+) and SKBr-3(ER−, HER2 overexpressing) breast cancer cell lines were
determined [Table 1]. These results provide evidence that compounds 14a, 14b, 14c, and
11c are the most potent analogues prepared in this series. The structure–activity
relationships suggest that analogues bearing sterically demanding side chains exhibit greater
potency, as compounds with biaryl, indole, or homologated aryl groups (11–14) were more
efficacious than substituted aryl compounds (6–10). In addition, comparison of compounds
6–10 suggests that para-substitution of the aryl ring with Me, OMe, NMe2 or F is not well
tolerated, as these compounds displayed minimal anti-proliferative activity. These results
suggest that the C-terminal binding pocket has a large hydrophobic pocket that can easily
accommodate substituents as in compounds 11–14.
Additionally, comparision between the amide containing analogues and triazole containing
analogues provides further SAR [Table 2]. As evident from the data presented in Table 2,
the triazole moiety has little effect on anti-proliferative activity. Both the triazole and amide
analogues containing the biaryl and 3-indole side chains indicate the activities for both sets
of compounds are comparable against the two cell lines tested. One discrepancy observed
between the amide and triazole analogues is that in which simple aryl side chains (6–10)
manifest IC50 values in the 10–20 µM range for the amide–containing molecules while the
triazole compounds 6 and 9 display IC50 values above 50 µM.13 These results suggest that
the triazole moiety affects biological activity in two ways: the availability of a hydrogen
bond donor in the amide linkage and the steric bulk of the side chain. This hydrogen bond
contact is lost upon introduction of the triazole moiety, but can be overcome by the
introduction of steric bulk in the side chain. A preference for steric bulk has been observed
in several series of novobiocin analogues, and appears to be a contributing factor to
biological activity.
After analysis of the triazole containing analogues anti-proliferative activity, Western blot
analysis was preformed for the most active compound, 14b, to confirm anti-proliferative
activity results from Hsp90 inhibition [Figure 2]. Western blot analysis of MCF-7 cells
treated with increasing concentrations of 14b, induce Hsp90-dependent client protein
degradation in a dose-dependent manner, with an apparent IC50 value that correlates directly
to the anti-proliferative IC50 value. Her2 and c-Raf are client proteins of Hsp90, and
pharmacological inhibition of Hsp90 leads to their degradation via ubiquitinylation and
proteome-mediated hydrolysis. Additionally, compound 14b appears to have little effect on
the heat shock response, as unaltered levels of Hsp90 were observed, consistent with
inhibition of the Hsp90 C-terminus. In contrast, client protein degradation and heat shock
induction was not observed for the inactive compound 10b (data not shown). Western blot
analysis indicates that these compounds are interfering with the Hsp90-mediated protein
folding process, and that the anti-proliferative activities for these compounds are directly
related to Hsp90 inhibition.
In conclusion, a series of triazole containing novobiocin analogues was prepared and
evaluated against two breast cancer cell lines. Western blot analysis affirmed Hsp90
inhibition by this class of compounds. The compounds described herein exhibit comparable
activities to the corresponding amide-containing analogues. These results indicate that the
amide moiety can be replaced by the triazole functionality, however, in some cases the loss
of the hydrogen bond donor appears detrimental, but can be overcome by the inclusion of
steric bulk in the triazole substituent.
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Western blot analysis for compound 14b
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Reagents:(a) (i) POCl3, DMF, MeCN; (ii) H2O (55%); (b) N-acetyl glycine, NaOAc, Ac2O;
(c) HCl, EtOH (d) NaNO2, HCl, EtOH, H2O, then NaN3 (52% 3 steps); (e) Ac2O, pyridine,
CH2Cl2 (> 95%)
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"Click" procedure with various alkynes used. aThe TMS protected alkynes were used in
these reactions with the addition of 1 eq. TBAF
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Noviosylation of triazole appended coumarins.
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Table 2
Comparison of Anti-Proliferative Activies: Amide-Containing vs. Triazole-Containing Novobiocin Analogues
R = Biaryl R = Biaryl (11c)
IC50 (MCF-7) 18.7 ± 1.8a 13.16 ± 3.85
IC50 (SKBr-3) 7.5 ± 1.0a 21.22 ± 5.99
R = 3-Indole R = 3-Indole (14c)
IC50 (MCF-7) 5.3 ± 0.3a 18.33 ± 4.67
IC50 (SKBr-3) 12.2 ± 1.5a 8.17 ± 0.11
a
Biological data taken from Ref. [13]
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